Home  >  News
Corporate
+ Font Resize -

Dr. Reddy's Laboratories announces launch of Bivalirudin for Injection in the U.S. Market

Our Bureau, Bengaluru
Wednesday, June 07, 2017, 14:00 Hrs  [IST]

Dr. Reddy’s Laboratories has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax (Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).

The Angiomax brand and generic had US sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health. Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials. Angiomax is a registered trademark of The Medicines Company.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |